{
  "trial_id": "NCT00928434",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "18 years or older",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Raising PSA after prior treatment failure of localized prostate cancer",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Has a histological confirmed non-metastatic cancer of the prostate (Gleason graded) based on the most current biopsy",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Has a screening testosterone within normal range (\u22651.5 ng/mL)",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Has Eastern Cooperative Oncology Group score of \u22642",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Bone scan or CT scan report documenting no evidence of metastasis to the bone or internal organs",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Life expectancy of at least 15 months",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Taken hormone therapy in the last 6 months prior to entering this study",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Being treated with 5-alpha reductase inhibitor at time of enrolment and remained on a stable dose throughout the trial",
      "label": "not_met",
      "evidence": "none"
    }
  ],
  "notes": "Patient is eligible for the study based on the provided information. Further evaluation may be necessary to confirm eligibility.",
  "_meta": {
    "topic_id": "60",
    "trial_id": "NCT00928434",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}